<DOC>
	<DOCNO>NCT00004853</DOCNO>
	<brief_summary>Filgrastim ( granulocyte colony-stimulating factor ) , administer daily subcutaneous injection cytotoxic chemotherapy , shorten duration chemotherapy-induced neutropenia lower risk infection . In child treat dose-intensive chemotherapy , filgrastim reduces duration severe neutropenia , result , become standard component treatment regimen . Filgrastim-SD/01 ( AMGEN ) , produce PEGylation amino-terminus filgrastim , sustain duration form granulocyte colony-stimulating factor . In phase I phase II trial adult , single dose Filgrastim-SD/01 appear equivalent daily dose filgrastim enhance neutrophil recovery comparable adverse event profile . Dose-intensive vincristine/cyclophosphamide/doxorubicin ( VDoxC ) alternate ifosfamide/etoposide ( IE ) become standard therapy child adolescents Ewing 's sarcoma sarcoma treat POB/NCI cancer center within US . Supportive care measure use child treat regimen include mesna prevent oxazaphosphorine urotoxicity , dexrazoxane reduce doxorubicin cardiotoxicity , filgrastim shorten duration neutropenia . The purpose randomized open label trial compare tolerance , toxicity , therapeutic effect Filgrastim-SD/01 give single injection chemotherapy daily subcutaneous filgrastim patient newly diagnose sarcoma . The pharmacokinetics Filgrastim-SD/01 also compare pharmacokinetics filgrastim . This trial also platform perform biological study tumor detail cardiac study . High-risk patient treat front line trial respond also candidate plan transplant protocol . A total 34 patient ( 17 patient per treatment arm ) enter onto trial .</brief_summary>
	<brief_title>Comparison Filgrastim Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy</brief_title>
	<detailed_description>Background : - Filgrastim ( granulocyte colony-stimulating factor ) , administer daily subcutaneous injection cytotoxic chemotherapy , shorten duration chemotherapy-induced neutropenia lower risk infection . - In child treat dose-intensive chemotherapy , Filgrastim reduce duration severe neutropenia , result , become standard component treatment regimen . - Filgrastim-SD/01 ( AMGEN ) , produce PEGylation amino-terminus Filgrastim , sustain duration form granulocyte colony-stimulating factor . - In phase I phase II trial adult , single dose Filgrastim-SD/01 appear equivalent daily dose Filgrastim enhance neutrophil recovery comparable adverse event profile . - Dose-intensive vincristine/cyclophosphamide/doxorubicin ( VDoxC ) alternate ifosfamide/etoposide ( IE ) become standard therapy child adolescents Ewing 's sarcoma sarcoma treat POB/NCI cancer center within US . Objectives : - Compare tolerance , toxicity , therapeutic effect Filgrastim-SD/01 give single injection chemotherapy daily subcutaneous Filgrastim patient newly diagnose sarcoma receive multi-agent , dose intensive chemotherapy . - The pharmacokinetics Filgrastim-SD/01 also compare pharmacokinetics Filgrastim . - This trial also platform perform biological study tumor study neutrophil function CD34 mobilization , detailed cardiac study . Eligibility : - Children young adult ( less equal 25 year ) previously untreated high-risk sarcoma ( Ewing sarcoma , rhabdomyosarcoma , MPNST , synovial sarcoma ) . - No evidence tumor infiltration bone marrow . Design : - Participants randomize ( 1:1 ) receive single dose Filgrastim-SD/01 daily filgrastim SQ injection cycle chemotherapy . - Standard 5 drug dose-intensive chemotherapy vincristine , doxorubicin , cyclophosphamide alternate ifosfamide etoposide administer . - Surgery radiation primary tumor occur cycle 5 . - A total 34 patient ( 17 patient per treatment arm ) enter onto trial .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION CRITERIA : Newly diagnose histologically prove : Ewing 's sarcoma family tumor , include peripheral neuroectodermal tumor ; Alveolar rhabdomyosarcoma ; Stage 3 4 embryonal rhabdomyosarcoma ; Malignant peripheral nerve sheath tumor unresectable , incompletely resect bulk residual disease metastatic ; Synovial cell sarcoma unresectable , incompletely resect bulk residual disease , metastatic . Age equal less 25 year time diagnosis . Normal cardiac function ( ejection fraction MUGA ECHO within institutional normal range ) . Normal serum creatinine age creatinine clearance great 60 ml/min/1.73m ( 2 ) . Normal liver function ( SGPT less 5 time upper limit normal bilirubin le 2.5 time upper limit normal ) . Normal hematologic function ( absolute neutrophil count equal great 1500/microL , hemoglobin equal great 9.0 g/dl platelet count equal great 100,000/microL ) . Subjects childbearing childfathering potential must willing use medically acceptable form birth control , include abstinence , treat study . EXCLUSION CRITERIA : Previous chemotherapy radiotherapy . Pregnant breast feeding female chemotherapy administer trial could detrimental effect develop fetus newborn . Histological evidence tumor infiltration bone marrow . Stage 1 2 embryonal rhabdomyosarcoma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 27, 2016</verification_date>
	<keyword>AMGEN</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>MPNST</keyword>
	<keyword>Randomized</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Tumor</keyword>
</DOC>